Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
Cerebrolysin 60mg
3–7 days most of the EU · 8–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€13.99 · Same-day dispatch before 14:00 CET on weekdays · Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay — approve a SEPA transfer in your own bank via Paysera’s hosted page, or send a manual SEPA transfer using the IBAN we email you.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders placed before 14:00 CET on a weekday typically ship the same day.
Card payments are not currently offered. There is no card processor on this checkout.
Free shipping on orders over €200
Research-grade Cerebrolysin. ≥98% supplier batch specification; selected lots independently tested. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €28.99 | €28.99 | -- |
| 3+ | €27.54 | €82.62 | 5% off |
| 5+Most Popular | €26.09 | €130.45 | 10% off |
| 10+ | €24.64 | €246.41 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
View report #212145 on janoshik.com →
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
About Cerebrolysin 60mg
Cerebrolysin is a multi-peptide brain-derived neurotrophic preparation consisting of enzymatically treated porcine brain protein. The preparation contains a mixture of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier. It has an unusually long history for a peptide complex and has been studied in the context of neurological injury models including ischemic, traumatic, and vascular insults -- and has been characterised since the 1970s. Each vial contains 60mg of the lyophilized preparation.
The active components of Cerebrolysin are not fully defined chemically, which distinguishes it from single-compound neurotrophic peptides. The preparation has demonstrated neurotrophic factor-like activity in cell culture and animal models: it promotes neuronal survival, enhances synaptic plasticity, stimulates neurogenesis, and exhibits neuroprotective effects in various injury models. Preclinical and in-vitro studies have examined its effects on recovery and cognitive parameters in injury and neurodegeneration models, with variable results across study designs. The European Medicines Agency has characterised it within some neurological research contexts.
For research purposes, Cerebrolysin is a useful tool for studying multi-factor neurotrophic support -- where the combined effect of multiple small peptides may recapitulate some of the biological activity of endogenous neurotrophic factors (BDNF, NGF, GDNF) more completely than any single defined compound.
Specifications
| Parameter | Value |
|---|---|
| Compound | Cerebrolysin (porcine brain-derived neuropeptide complex) |
| Amount per Vial | 60mg lyophilized |
| Composition | Low-MW neuropeptides + free amino acids from porcine brain proteins |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | 2-8°C; use within 14 days after reconstitution |
Storage
Store at 2-8°C (refrigerator) as lyophilized powder. Refrigerate after reconstitution and use within 14 days. As a biological preparation, avoid freezing and thawing cycles.
What makes Cerebrolysin different from a single neurotrophic peptide?
Single neurotrophic peptides (like BDNF or NGF) target specific receptors. Cerebrolysin contains a mixture of multiple small peptides and amino acids that together mimic aspects of the brain's complex neurotrophic environment. In research, this can be advantageous when the goal is broad neuroprotection or neurogenesis stimulation rather than receptor-specific pharmacology. The trade-off is that the mixture composition is not fully defined, which limits mechanistic interpretation. Cerebrolysin is better suited for studies where the preparation itself is the research focus, or for generating hypotheses that can then be pursued with defined single compounds.
How does Cerebrolysin penetrate the blood-brain barrier?
Cerebrolysin's active components are specifically the low-molecular-weight fraction (peptides under approximately 10 kDa) -- the preparation is enzymatically processed to ensure these small peptides predominate. Small peptides can cross the blood-brain barrier through passive diffusion (if sufficiently lipophilic), transcytosis, or active transport. The preparation is documented to produce measurable CNS effects after systemic IV or IM administration in preclinical models, indicating at least partial CNS delivery. The full pharmacokinetics of the mixed preparation are complex to characterize precisely.
What are the main research areas for Cerebrolysin?
The most-studied research area for Cerebrolysin is ischemic injury models -- preclinical work has examined neurological outcome parameters when administered early in models of ischemic insult. Neurodegeneration models have examined cognitive parameters in some studies but not consistently across designs. Traumatic injury models have been another focus, with preclinical data examining neuroprotection. The research base is heterogeneous in quality, and the compound is characterised differently across regulatory jurisdictions.
Cerebrolysin is supplied for laboratory research use only. Not for human consumption. Handle in compliance with institutional biosafety guidelines.
Specification Summary
About Cerebrolysin 60mg
Cerebrolysin is a multi-peptide brain-derived neurotrophic preparation consisting of enzymatically treated porcine brain protein. The preparation contains a mixture of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier. It has an unusually long history for a peptide complex and has been studied in the context of neurological injury models including ischemic, traumatic, and vascular insults -- and has been characterised since the 1970s. Each vial contains 60mg of the lyophilized preparation.
The active components of Cerebrolysin are not fully defined chemically, which distinguishes it from single-compound neurotrophic peptides. The preparation has demonstrated neurotrophic factor-like activity in cell culture and animal models: it promotes neuronal survival, enhances synaptic plasticity, stimulates neurogenesis, and exhibits neuroprotective effects in various injury models. Preclinical and in-vitro studies have examined its effects on recovery and cognitive parameters in injury and neurodegeneration models, with variable results across study designs. The European Medicines Agency has characterised it within some neurological research contexts.
For research purposes, Cerebrolysin is a useful tool for studying multi-factor neurotrophic support -- where the combined effect of multiple small peptides may recapitulate some of the biological activity of endogenous neurotrophic factors (BDNF, NGF, GDNF) more completely than any single defined compound.
Specifications
| Parameter | Value |
|---|---|
| Compound | Cerebrolysin (porcine brain-derived neuropeptide complex) |
| Amount per Vial | 60mg lyophilized |
| Composition | Low-MW neuropeptides + free amino acids from porcine brain proteins |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | 2-8°C; use within 14 days after reconstitution |
Storage
Store at 2-8°C (refrigerator) as lyophilized powder. Refrigerate after reconstitution and use within 14 days. As a biological preparation, avoid freezing and thawing cycles.
What makes Cerebrolysin different from a single neurotrophic peptide?
Single neurotrophic peptides (like BDNF or NGF) target specific receptors. Cerebrolysin contains a mixture of multiple small peptides and amino acids that together mimic aspects of the brain's complex neurotrophic environment. In research, this can be advantageous when the goal is broad neuroprotection or neurogenesis stimulation rather than receptor-specific pharmacology. The trade-off is that the mixture composition is not fully defined, which limits mechanistic interpretation. Cerebrolysin is better suited for studies where the preparation itself is the research focus, or for generating hypotheses that can then be pursued with defined single compounds.
How does Cerebrolysin penetrate the blood-brain barrier?
Cerebrolysin's active components are specifically the low-molecular-weight fraction (peptides under approximately 10 kDa) -- the preparation is enzymatically processed to ensure these small peptides predominate. Small peptides can cross the blood-brain barrier through passive diffusion (if sufficiently lipophilic), transcytosis, or active transport. The preparation is documented to produce measurable CNS effects after systemic IV or IM administration in preclinical models, indicating at least partial CNS delivery. The full pharmacokinetics of the mixed preparation are complex to characterize precisely.
What are the main research areas for Cerebrolysin?
The most-studied research area for Cerebrolysin is ischemic injury models -- preclinical work has examined neurological outcome parameters when administered early in models of ischemic insult. Neurodegeneration models have examined cognitive parameters in some studies but not consistently across designs. Traumatic injury models have been another focus, with preclinical data examining neuroprotection. The research base is heterogeneous in quality, and the compound is characterised differently across regulatory jurisdictions.
Cerebrolysin is supplied for laboratory research use only. Not for human consumption. Handle in compliance with institutional biosafety guidelines.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
